Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
Vical Incorporated (Nasdaq:VICL) announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine....... The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial...Experimental therapies and vaccines for Ebola and Marburg viruses focus of Academy meeting
Recent outbreaks of Ebola and Marburg virus infections in Africa have been characterized by two remarkable features they have been unusually sustained and have maintained extremely high fatality rates. These two features have underscored the need to expand our current understanding of these fatal hemorrhagic diseases and to accelerate progress towards protective vaccines and novel therapeutic s...Ebola virus reproduction in laboratory-grown cells is severely hampered by enzyme-inhibiting chemicals, and these chemicals deserve further study as possible treatments for Ebola virus infections in humans, report scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). ......The researchers, whose p...